 Eric Hink
Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Orbit | 7 | 2024 | 57 | 1.740 |
Why?
| | Eyelids | 7 | 2024 | 34 | 1.700 |
Why?
| | Eyelid Diseases | 5 | 2024 | 18 | 1.660 |
Why?
| | Orbital Fractures | 4 | 2017 | 9 | 1.110 |
Why?
| | Surgical Mesh | 1 | 2024 | 46 | 0.860 |
Why?
| | Titanium | 1 | 2024 | 79 | 0.840 |
Why?
| | Tetralogy of Fallot | 1 | 2024 | 78 | 0.840 |
Why?
| | Oculomotor Muscles | 3 | 2017 | 37 | 0.790 |
Why?
| | Sarcoma, Kaposi | 1 | 2022 | 76 | 0.770 |
Why?
| | Eye Infections, Bacterial | 4 | 2015 | 27 | 0.750 |
Why?
| | Ophthalmologic Surgical Procedures | 7 | 2015 | 56 | 0.720 |
Why?
| | Eye Infections, Fungal | 3 | 2017 | 7 | 0.690 |
Why?
| | Orbital Diseases | 2 | 2017 | 28 | 0.680 |
Why?
| | Down Syndrome | 1 | 2024 | 469 | 0.560 |
Why?
| | Sphenoid Bone | 1 | 2017 | 15 | 0.560 |
Why?
| | Skull Neoplasms | 1 | 2017 | 23 | 0.560 |
Why?
| | Meningioma | 1 | 2017 | 81 | 0.520 |
Why?
| | Blepharophimosis | 1 | 2013 | 3 | 0.430 |
Why?
| | Candidiasis | 1 | 2013 | 53 | 0.420 |
Why?
| | Eye Injuries | 2 | 2014 | 45 | 0.400 |
Why?
| | Prostheses and Implants | 3 | 2024 | 136 | 0.400 |
Why?
| | Orbital Cellulitis | 3 | 2015 | 15 | 0.360 |
Why?
| | Conjunctiva | 1 | 2011 | 51 | 0.360 |
Why?
| | Surgical Wound Infection | 1 | 2013 | 277 | 0.340 |
Why?
| | Golf | 1 | 2008 | 7 | 0.310 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2013 | 354 | 0.300 |
Why?
| | Tomography, X-Ray Computed | 9 | 2017 | 2523 | 0.280 |
Why?
| | Inflammation | 1 | 2017 | 2654 | 0.260 |
Why?
| | Alprostadil | 1 | 2024 | 32 | 0.220 |
Why?
| | Orbital Neoplasms | 3 | 2015 | 20 | 0.220 |
Why?
| | Humans | 31 | 2024 | 128417 | 0.220 |
Why?
| | Child, Preschool | 10 | 2017 | 10384 | 0.220 |
Why?
| | Surgical Flaps | 3 | 2015 | 137 | 0.210 |
Why?
| | Syndrome | 1 | 2024 | 335 | 0.210 |
Why?
| | Eye Burns | 1 | 2022 | 11 | 0.200 |
Why?
| | Compartment Syndromes | 1 | 2022 | 31 | 0.200 |
Why?
| | Dacryocystorhinostomy | 2 | 2015 | 9 | 0.200 |
Why?
| | Optic Nerve | 1 | 2022 | 65 | 0.190 |
Why?
| | Eye | 1 | 2022 | 103 | 0.190 |
Why?
| | Injections | 1 | 2022 | 172 | 0.190 |
Why?
| | Mucormycosis | 2 | 2017 | 21 | 0.170 |
Why?
| | Adolescent | 13 | 2017 | 20179 | 0.170 |
Why?
| | Cicatrix | 2 | 2017 | 58 | 0.160 |
Why?
| | Eye Pain | 2 | 2017 | 7 | 0.160 |
Why?
| | Retrospective Studies | 10 | 2022 | 14454 | 0.150 |
Why?
| | Child | 11 | 2017 | 20655 | 0.150 |
Why?
| | Male | 16 | 2024 | 62857 | 0.150 |
Why?
| | Neoplasm Invasiveness | 2 | 2017 | 480 | 0.150 |
Why?
| | Mucocele | 1 | 2017 | 12 | 0.140 |
Why?
| | Mucorales | 1 | 2017 | 1 | 0.140 |
Why?
| | Paranasal Sinus Diseases | 1 | 2017 | 15 | 0.140 |
Why?
| | Graves Ophthalmopathy | 1 | 2017 | 9 | 0.140 |
Why?
| | Nose Diseases | 1 | 2017 | 12 | 0.140 |
Why?
| | Critical Care | 1 | 2022 | 541 | 0.140 |
Why?
| | Conjunctival Diseases | 1 | 2017 | 17 | 0.140 |
Why?
| | Amnion | 1 | 2017 | 25 | 0.140 |
Why?
| | Floods | 1 | 2017 | 17 | 0.140 |
Why?
| | Receptor, IGF Type 1 | 1 | 2017 | 65 | 0.140 |
Why?
| | Corneal Diseases | 1 | 2017 | 34 | 0.140 |
Why?
| | Soft Tissue Injuries | 1 | 2017 | 39 | 0.140 |
Why?
| | Visual Acuity | 4 | 2017 | 322 | 0.140 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2017 | 38 | 0.130 |
Why?
| | Craniotomy | 1 | 2017 | 68 | 0.130 |
Why?
| | Endoscopy | 2 | 2017 | 266 | 0.130 |
Why?
| | Diagnosis, Differential | 3 | 2017 | 1416 | 0.130 |
Why?
| | Vision Disorders | 1 | 2017 | 136 | 0.130 |
Why?
| | Streptococcal Infections | 3 | 2015 | 144 | 0.130 |
Why?
| | Infant | 6 | 2017 | 8914 | 0.130 |
Why?
| | Disasters | 1 | 2017 | 91 | 0.130 |
Why?
| | Cavernous Sinus Thrombosis | 1 | 2015 | 9 | 0.120 |
Why?
| | Lacrimal Apparatus | 1 | 2015 | 7 | 0.120 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2015 | 5 | 0.120 |
Why?
| | Polyglycolic Acid | 1 | 2015 | 41 | 0.120 |
Why?
| | Absorbable Implants | 1 | 2015 | 35 | 0.120 |
Why?
| | Immunologic Factors | 1 | 2017 | 225 | 0.120 |
Why?
| | Biopsy | 2 | 2017 | 1081 | 0.120 |
Why?
| | Female | 17 | 2017 | 68153 | 0.120 |
Why?
| | Prednisone | 1 | 2015 | 230 | 0.110 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2014 | 11 | 0.110 |
Why?
| | Facial Paralysis | 1 | 2014 | 17 | 0.110 |
Why?
| | Follow-Up Studies | 4 | 2014 | 4892 | 0.110 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2015 | 158 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 5 | 2017 | 3376 | 0.110 |
Why?
| | Exophthalmos | 2 | 2017 | 17 | 0.110 |
Why?
| | Adult | 10 | 2022 | 35299 | 0.110 |
Why?
| | Osteotomy | 1 | 2015 | 162 | 0.110 |
Why?
| | School Admission Criteria | 1 | 2013 | 23 | 0.110 |
Why?
| | Platinum | 1 | 2014 | 44 | 0.110 |
Why?
| | Mycobacterium chelonae | 1 | 2013 | 8 | 0.110 |
Why?
| | Silicone Elastomers | 1 | 2013 | 8 | 0.110 |
Why?
| | Lactic Acid | 1 | 2015 | 293 | 0.110 |
Why?
| | Analgesics | 1 | 2015 | 163 | 0.110 |
Why?
| | Surgery, Plastic | 1 | 2013 | 33 | 0.110 |
Why?
| | Jaw Fractures | 1 | 2013 | 2 | 0.110 |
Why?
| | Facial Bones | 1 | 2013 | 28 | 0.100 |
Why?
| | Skull Fractures | 1 | 2013 | 33 | 0.100 |
Why?
| | Bites and Stings | 1 | 2013 | 28 | 0.100 |
Why?
| | C-Reactive Protein | 1 | 2015 | 397 | 0.100 |
Why?
| | Eye Injuries, Penetrating | 1 | 2013 | 16 | 0.100 |
Why?
| | Gold | 1 | 2014 | 118 | 0.100 |
Why?
| | Sinusitis | 1 | 2015 | 202 | 0.100 |
Why?
| | Pain, Postoperative | 1 | 2015 | 225 | 0.100 |
Why?
| | Eye Foreign Bodies | 1 | 2013 | 23 | 0.100 |
Why?
| | Suture Techniques | 1 | 2013 | 121 | 0.100 |
Why?
| | Ophthalmology | 1 | 2013 | 82 | 0.100 |
Why?
| | Aged, 80 and over | 6 | 2015 | 7033 | 0.100 |
Why?
| | Craniocerebral Trauma | 1 | 2014 | 151 | 0.100 |
Why?
| | Dogs | 1 | 2013 | 366 | 0.100 |
Why?
| | Middle Aged | 9 | 2017 | 30889 | 0.100 |
Why?
| | Adenoma | 1 | 2014 | 213 | 0.100 |
Why?
| | Glucocorticoids | 1 | 2015 | 571 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1355 | 0.090 |
Why?
| | Fellowships and Scholarships | 1 | 2013 | 272 | 0.090 |
Why?
| | Endophthalmitis | 1 | 2010 | 28 | 0.090 |
Why?
| | Retinal Neoplasms | 1 | 2010 | 26 | 0.080 |
Why?
| | Retinoblastoma | 1 | 2010 | 31 | 0.080 |
Why?
| | Fracture Fixation, Internal | 1 | 2013 | 224 | 0.080 |
Why?
| | Intraoperative Complications | 1 | 2011 | 130 | 0.080 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 435 | 0.080 |
Why?
| | Streptococcus agalactiae | 1 | 2010 | 93 | 0.080 |
Why?
| | Persistent Fetal Circulation Syndrome | 1 | 2010 | 136 | 0.080 |
Why?
| | Blindness | 1 | 2008 | 37 | 0.070 |
Why?
| | Burkitt Lymphoma | 1 | 2008 | 56 | 0.070 |
Why?
| | Aged | 7 | 2017 | 21953 | 0.070 |
Why?
| | Decision Making | 1 | 2014 | 847 | 0.070 |
Why?
| | Age Factors | 1 | 2014 | 3103 | 0.070 |
Why?
| | Sweat Gland Neoplasms | 1 | 2006 | 5 | 0.060 |
Why?
| | Eyelid Neoplasms | 1 | 2006 | 9 | 0.060 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2006 | 75 | 0.060 |
Why?
| | Biomarkers | 1 | 2015 | 3880 | 0.060 |
Why?
| | Treatment Outcome | 3 | 2017 | 10151 | 0.050 |
Why?
| | Postoperative Complications | 2 | 2013 | 2485 | 0.050 |
Why?
| | Double-Blind Method | 2 | 2017 | 1848 | 0.050 |
Why?
| | Staphylococcal Infections | 2 | 2015 | 379 | 0.040 |
Why?
| | Anti-Bacterial Agents | 3 | 2015 | 1663 | 0.040 |
Why?
| | Intraocular Pressure | 1 | 2022 | 295 | 0.040 |
Why?
| | Young Adult | 2 | 2017 | 12312 | 0.040 |
Why?
| | Prospective Studies | 3 | 2015 | 7036 | 0.040 |
Why?
| | Diplopia | 1 | 2017 | 17 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 68 | 0.030 |
Why?
| | Ocular Motility Disorders | 1 | 2017 | 26 | 0.030 |
Why?
| | Decompression, Surgical | 1 | 2017 | 99 | 0.030 |
Why?
| | Nasolacrimal Duct | 1 | 2015 | 7 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2017 | 194 | 0.030 |
Why?
| | Diabetes Complications | 1 | 2017 | 223 | 0.030 |
Why?
| | Pregabalin | 1 | 2015 | 8 | 0.030 |
Why?
| | Blepharoplasty | 1 | 2015 | 8 | 0.030 |
Why?
| | Perioperative Period | 1 | 2015 | 48 | 0.030 |
Why?
| | Bone Nails | 1 | 2015 | 67 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2015 | 161 | 0.030 |
Why?
| | Hyperglycemia | 1 | 2017 | 326 | 0.030 |
Why?
| | Administration, Oral | 1 | 2015 | 754 | 0.030 |
Why?
| | Pain Measurement | 1 | 2015 | 487 | 0.020 |
Why?
| | ROC Curve | 1 | 2014 | 500 | 0.020 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 212 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 1974 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 755 | 0.020 |
Why?
| | Pain Management | 1 | 2015 | 318 | 0.020 |
Why?
| | Foreign Bodies | 1 | 2013 | 101 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2014 | 5687 | 0.020 |
Why?
| | Microscopy, Acoustic | 1 | 2010 | 8 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1269 | 0.020 |
Why?
| | Eye Enucleation | 1 | 2010 | 11 | 0.020 |
Why?
| | Athletic Injuries | 1 | 2017 | 517 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2616 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1204 | 0.020 |
Why?
| | Length of Stay | 1 | 2015 | 1113 | 0.020 |
Why?
| | Etoposide | 1 | 2008 | 149 | 0.020 |
Why?
| | Maxilla | 1 | 2007 | 33 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2008 | 227 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4375 | 0.020 |
Why?
| | Methotrexate | 1 | 2008 | 248 | 0.020 |
Why?
| | Doxorubicin | 1 | 2008 | 322 | 0.020 |
Why?
| | Mohs Surgery | 1 | 2006 | 25 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 3772 | 0.020 |
Why?
| | Quality of Life | 1 | 2017 | 2680 | 0.020 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2006 | 209 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 5362 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1559 | 0.010 |
Why?
| | United States | 1 | 2013 | 13830 | 0.010 |
Why?
| | Animals | 1 | 2013 | 34479 | 0.010 |
Why?
|
|
Hink's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|